Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study

References

• Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975–2012. Volume II: college students and adults 19–50. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2013.
   Google Scholar
• Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 2001;16:457–469.
   PubMed Web of Science ®Google Scholar
• Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev 2014; 18:477–487.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Poot-Ake A, Arias-Carrion O, Pacheco-Pantoja E, Fuente-Ortegon A, Arankowsky-Sandoval G. The emerging role of the endocannabinoid system in the sleep-wake cycle modulation. Cent Nerv Syst Agents Med Chem 2011;11:189–196.
   PubMedGoogle Scholar
• Goonawardena A, Plano A, Robinson L, Ross R, Greig I, Pertwee R, Hampson RE, Platt B, Riedel G. Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. Behav Pharmacol 2015; 26:289–303.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani P. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 2003; 26:943–947.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Cabeza R, Mendez-Diaz M, Navarro L, Prospero-Garcia O. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 2001;12:2131–2136.
   PubMed Web of Science ®Google Scholar
• Santucci V, Storme J, Soubrié P, Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996;58:PL103–PL110.
   PubMed Web of Science ®Google Scholar
• Pava MJ, den Hartog CR, Blanco-Centurion C, Shiromani PJ, Woodward JJ. Endocannabinoid modulation of cortical up-states and NREM Sleep. PLoS One 2014;9:e88672.
   Google Scholar
• Herrera-Solís A, Vásquez K, Prospéro-García O. Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. Pharmacol Biochem Behav 2010;95:106–112.
   PubMed Web of Science ®Google Scholar
• Méndez-Díaz M, Caynas-Rojas S, Santacruz V, Ruiz-Contreras A, Aguilar-Roblero R, Prospéro-García O. Entopeduncular nucleus endocannabinoid system modulates sleep–waking cycle and mood in rats. Pharmacol Biochem Behav 2013;107:29–35.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Sánchez-Alavez M, Navarro L, Martinez-González D, Drucker-Colı́n R, Prospéro-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res 1998;812:270–274.
   PubMed Web of Science ®Google Scholar
• Rueda-Orozco P, Soria-Gómez E, Montes-Rodríguez C, Pérez-Morales M, Prospéro-García O. Intrahippocampal administration of anandamide increases REM sleep. Neurosci Lett 2010;473:158–162.
   PubMed Web of Science ®Google Scholar
• Huitron-Resendiz S, Sanchez-Alavez M, Wills DN, Cravatt BF, Henriksen SJ. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep 2004;27:857–865.
   PubMed Web of Science ®Google Scholar
• Chait L. Subjective and behavioral effects of marijuana the morning after smoking. Psychopharmacology 1990;100:328–333.
   PubMed Web of Science ®Google Scholar
• Cousens K, DiMascio A. (-) Delta 9 THC as an hypnotic: an experimental study of three dose levels. Psychopharmacologia 1973;33:355–364.
   PubMed Web of Science ®Google Scholar
• Gorelick DA, Goodwin RS, Schwilke E, Schroeder JR, Schwope DM, Kelly DL, Ortemann-Renon C, Bonnet D, Huestis MA. Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. Am J Addict 2013;22:510–514.
   PubMed Web of Science ®Google Scholar
• Nicholson A, Turner C, Stone B, Robson P. Effect of delta 9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 2004;24:305–313.
   PubMed Web of Science ®Google Scholar
• Karacan I, Fernandez Salas A, Coggins WJ. Sleep electroencephalographic characteristics of chronic marijuana users. I. Ann N YAcad Sci 1976;282:348e74.
   Google Scholar
• Colten HR, Altevogt BM. Sleep physiology. In: Colten HR, Altevogt BM, ed. Sleep disorders and sleep deprivation: an unmet public health problem. Washington, DC: The National Academies Press; 2006: 33–53.
   Google Scholar
• Feinberg I, Jones R, Walker JM, Cavness C, March J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther 1975;17:458–466.
   PubMed Web of Science ®Google Scholar
• Freemon FR. The effect of Delta 9-tetrahydrocannabinol on sleep. Psychopharmacology 1974;35:39–44.
   Web of Science ®Google Scholar
• Tassinari CA, Ambrosetto G, Peraita-Adrado MR, Gastaut H. The neuropsychiatric syndrome of Δ⁹-tetrahydrocannabinol and cannabis intoxication in naïve subjects: a clinical and polygraphic study during wakefulness and sleep. In: Nahas, GG, et al. eds. Marihuana and medicine. New York, NY: Humana Press; 1999: 649–664.
   Google Scholar
• Chagas MHN, Crippa JAS, Zuardi AW, Hallak JEC, Machado-de-Sousa JP, Hirotsu C, Maia L, Tufik S, Andersen M. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol 2013;27:312–316.
   PubMed Web of Science ®Google Scholar
• Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology 1977;55:263–265.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Sarro-Ramirez A, Sanchez D, Mijangos-Moreno S, Tejeda-Padron A, Poot-Ake A, Guzman K, Pacheco-Pantoja E, Arias-Carrion O. Potential effects of cannabidiol as a wake-promoting agent. Curr Neuropharmacol 2014;12:269–272.
   PubMed Web of Science ®Google Scholar
• Cohen-Zion M, Drummond SP, Padula CB, Winward J, Kanady J, Medina KL, Tapert SF. Sleep architecture in adolescent marijuana and alcohol users during acute and extended abstinence. Addict Behav 2009;34:976–979.
   PubMed Web of Science ®Google Scholar
• Dijk D. Regulation and functional correlates of slow wave sleep. J Clin Sleep Med 2009;5:S6–S15.
   PubMedGoogle Scholar
• Gillin JC, Drummond SPA. Medication and substance use. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. Philadelphia, PA: W.B. Saunders Company; 2000:1176–1195.
   Google Scholar
• Fairman BJ, Anthony JC. Are early-onset cannabis smokers at an increased risk of depression spells? J Affect Disord 2012;138:54–62.
   PubMed Web of Science ®Google Scholar
• Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: a cohort study. BMJ 2002;325:1195–98.
   PubMed Web of Science ®Google Scholar
• Rasic D, Weerasinghe S, Asbridge M, Langille DB. Longitudinal associations of cannabis and illicit drug use with depression, suicidal ideation and suicidal attempts among Nova Scotia high school students. Drug Alcohol Depend 2013;129:49–53.
   PubMed Web of Science ®Google Scholar
• van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 2007;102:1251–1260.
   PubMed Web of Science ®Google Scholar
• Rey JM, Tennant CC. Cannabis and mental health. BMJ 2002;325:1183–1184.
   PubMed Web of Science ®Google Scholar
• Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 2007;46:408–417.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 2013;54:589–598.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, Lieb R, Perkonigg A. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007;88:S60–S70.
   PubMed Web of Science ®Google Scholar
• Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 2007;48:592–600.
   PubMed Web of Science ®Google Scholar
• Medina KL, Shear PK. Anxiety, depression, & behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug Alcohol Depend 2007;87:303–311.
   PubMed Web of Science ®Google Scholar
• McQueeny T, Padula CB, Price JS, Medina KL, Logan P, Tapert SF. Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 2011;224:128–134.
   PubMed Web of Science ®Google Scholar
• Hillard C, Weinlander K, Stuhr K. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012;204:207–229.
   PubMed Web of Science ®Google Scholar
• Witkin J, Tzavara E, Nomikos G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005;16:315–331.
   PubMed Web of Science ®Google Scholar
• Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 2005;19:293–300.
   PubMed Web of Science ®Google Scholar
• Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002;159:379–387.
   PubMed Web of Science ®Google Scholar
• Hill M, Gorzalka B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005;15:593–599.
   PubMed Web of Science ®Google Scholar
• Adamczyk P, Golda A, McCreary A, Filip M, Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008;59:217–228.
   PubMed Web of Science ®Google Scholar
• Barrero F, Ampuero I, Morales B, Vives F, De Dios Luna Del Castillo J, Hoenicka J, Yébene-Garcia J. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). The Pharmacogenomics J 2005;5:135–141.
   Google Scholar
• Mitjans M, Serretti A, Fabbri C, Gastó C, Catalán R, Fañanás L, Arias B. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology 2013;227:509–519.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto M, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G, Bogetto F, Maj M. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010;61:400–404.
   PubMed Web of Science ®Google Scholar
• Baglioni C, Spiegelhalder K, Lombardo C, Riemann D. Sleep and emotions: a focus on insomnia. Sleep Med Rev 2010;14:227–238.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction 2009;104:518–532.
   PubMed Web of Science ®Google Scholar
• Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Hunyady L, Juhasz G, Bagdy G. Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am J Med Genet B Neuropsychiatr Genet 2009;150B:1118–1127.
   Google Scholar
• Lisdahl KM, Price JS. Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc 2012;18:678–688.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
   Google Scholar
• Goodwin RS, Darwin WD, Chiang CN, Shih M, Li S-H, Huestis MA. Urinary elimination of 11-nor-9-carboxy-9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008;32:562–569.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Maisto SA, Sobell MB, Cooper AM. Reliability of alcohol abusers’ self-reports of drinking behavior. Behav Res Ther 1979;17:157–160.
   PubMed Web of Science ®Google Scholar
• Brown SA, Meyer MG, Lippke L, Tapert SF, Stewart DG, Vik PW. Psychometric evaluation of the customary drinking and drug use record (CDDR): a measure of adolescent alcohol and drug involvement. J Stud Alcohol 1998;59:427–438.
   PubMed Web of Science ®Google Scholar
• Stewart DG, Brown SA. Withdrawal and dependency symptoms among adolescent alcohol and drug abusers. Addiction 1995;90:627–635.
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corporation; 1996.
   Google Scholar
• Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res 1989;28:193–213.
   PubMed Web of Science ®Google Scholar
• Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–1182.
   PubMed Web of Science ®Google Scholar
• Flanagan J, Gerber A, Cadet J, Beutler E, Sipe J. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 2006;120:581–588.
   PubMed Web of Science ®Google Scholar
• Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex®, a cannabis-based medicine. Chem Biodivers 2007;4:1729–1743.
   PubMed Web of Science ®Google Scholar
• Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9:254–264.
   PubMed Web of Science ®Google Scholar
• Neff GW, O’Brien CB, Rajender Reddy K, Bergasa ND, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117–2119.
   PubMed Web of Science ®Google Scholar
• Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther 2015;97:607–615.
   PubMed Web of Science ®Google Scholar
• Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addict Behav 2015;50:178–181.
   PubMed Web of Science ®Google Scholar
• Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly, MA. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010;55:1209–1217.
   Google Scholar
• Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013;8:e70052.
   PubMed Web of Science ®Google Scholar
• Budney A, Hughes J, Moore B, Novy P. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 2001;58:917–924.
   PubMed Web of Science ®Google Scholar
• Haney M, Ward A, Comer S, Foltin R, Fischman M. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999;141:395–404.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003;112:393–402.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642–649.
   PubMed Web of Science ®Google Scholar
• Whitehurst LN, Fogler K, Hall K, Hartmann M, Dyche J. The effects of chronic marijuana use on circadian entrainment. Chronobiol Int 2015;32:561–567.
   PubMed Web of Science ®Google Scholar
• Dlugos A, Hamidovic A, Hodgkinson C, Goldman D, Palmer A, de Wit H. More aroused, less fatigued: fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine. Neuropsychopharmacology 2010;35:613–622.
   PubMed Web of Science ®Google Scholar
• Winham SJ, Biernacka JM. Gene-environment interactions in genome-wide association studies: current approaches and new directions. J Child Psychol Psychiatry 2013;54:1–24.
   PubMed Web of Science ®Google Scholar